Pulmonary Hypertension | Treatment Algorithms: Claims Data Analysis | US | 2020
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. A wide array of drugs are available to treat PAH. Phosphodiesterase 5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs) are the most commonly prescribed first-line treatments; the more-efficacious prostacyclin therapies are used in later lines. Branded therapies dominate the PAH treatment algorithm, and combination therapy is common.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PAH patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PAH patients?
- How have Uptravi, Orenitram, Remodulin, and Adempas been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of PAH patients receive drug therapy within two years of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What percentage of PAH patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
KEY DRUGS COVERED
- Adcirca, Tracleer, Letairis, Opsumit, Tyvaso, Ventavis, Orenitram, Uptravi, Remodulin, Adempas, sildenafil, epoprostenol
Related Market Assessment Reports
Report
Gene Therapy – Access & Reimbursement – Access & Reimbursement – Gene Therapies for Rare Diseases (US)
With the increasing number of approved innovative, high-cost gene therapies, value assessment and novel reimbursement approaches are rapidly gaining importance. To assist developers of gene…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder of the hair follicles, characterized by painful, inflamed lesions often filled with fluid or pus. AbbVie’s Humira (…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (US)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAAD) is a rare autoimmune inflammatory CNS disorder defined by IgG antibodies targeting the myelin oligodendrocyte glycoprotein…
